Artículos

What should a psychiatrist know about genetics? / John I. Nurnberger en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No.1 (Enero - Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 10-15 Título : What should a psychiatrist know about genetics? : Review and recommendations from the residency education committee of the international society of psychiatric genetics Tipo de documento: texto impreso Autores: John I. Nurnberger, Autor ; Jehannine Austin, Autor ; Wade H. Berrettini, Autor Fecha de publicación: 2019 Artículo en la página: pp. 10-15 Idioma : Inglés (eng) Palabras clave: Genética psiquiátrica, Genómica Resumen: The International Society of Psychiatric Genetics (ISPG) created a Residency Education Committee with the purpose of identifying key genetic knowledge that should be taught in psychiatric training programs. Link: ./index.php?lvl=notice_display&id=20472 [artículo] What should a psychiatrist know about genetics? : Review and recommendations from the residency education committee of the international society of psychiatric genetics [texto impreso] / John I. Nurnberger, Autor ; Jehannine Austin, Autor ; Wade H. Berrettini, Autor . - 2019 . - pp. 10-15. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 10-15 Palabras clave: Genética psiquiátrica, Genómica Resumen: The International Society of Psychiatric Genetics (ISPG) created a Residency Education Committee with the purpose of identifying key genetic knowledge that should be taught in psychiatric training programs. Link: ./index.php?lvl=notice_display&id=20472

Abrupt symptom improvements in antidepressant clinical trials / Sigal Zilcha-Mano en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No.1 (Enero - Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 16-21 Título : Abrupt symptom improvements in antidepressant clinical trials : Transient placebo effects or therapeutic reality? Tipo de documento: texto impreso Autores: Sigal Zilcha-Mano, Autor ; Steven P. Roose, Autor ; Patrick J. Brown, Autor Fecha de publicación: 2019 Artículo en la página: pp. 16-21 Idioma : Inglés (eng) Palabras clave: Antidepresivos - mejoras abruptas, Terapéutica Resumen: According to prevailing models and classical reports, abrupt responses to antidepressant medication are not true drug responses but rather transient placebo effects. Link: ./index.php?lvl=notice_display&id=20473 [artículo] Abrupt symptom improvements in antidepressant clinical trials : Transient placebo effects or therapeutic reality? [texto impreso] / Sigal Zilcha-Mano, Autor ; Steven P. Roose, Autor ; Patrick J. Brown, Autor . - 2019 . - pp. 16-21. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 16-21 Palabras clave: Antidepresivos - mejoras abruptas, Terapéutica Resumen: According to prevailing models and classical reports, abrupt responses to antidepressant medication are not true drug responses but rather transient placebo effects. Link: ./index.php?lvl=notice_display&id=20473

Enhancing the treatment of patients with schizophrenia through continuous care / John Lauriello en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No.1 (Enero - Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 22-29 Título : Enhancing the treatment of patients with schizophrenia through continuous care Tipo de documento: texto impreso Autores: John Lauriello, Autor ; Diana O. Perkins, Autor Fecha de publicación: 2019 Artículo en la página: pp. 22-29 Idioma : Inglés (eng) Palabras clave: Esquizofrenia - tratamiento - atención continua Resumen: Schizophrenia is a chronic disorder that can be effectively controlled but will likely require lifelong treatment. Unfortunately, most patients experience numerous relapses, ongoing symptoms, and impairment, often because of treatment interruptions. Link: ./index.php?lvl=notice_display&id=20474 [artículo] Enhancing the treatment of patients with schizophrenia through continuous care [texto impreso] / John Lauriello, Autor ; Diana O. Perkins, Autor . - 2019 . - pp. 22-29. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 22-29 Palabras clave: Esquizofrenia - tratamiento - atención continua Resumen: Schizophrenia is a chronic disorder that can be effectively controlled but will likely require lifelong treatment. Unfortunately, most patients experience numerous relapses, ongoing symptoms, and impairment, often because of treatment interruptions. Link: ./index.php?lvl=notice_display&id=20474

Deaths by suicide and other causes among patients with borderline personality disorder and personality-disordered comparison subjects over 24 years of prospective follow-up / Christina M. Temes en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No.1 (Enero - Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 30-36 Título : Deaths by suicide and other causes among patients with borderline personality disorder and personality-disordered comparison subjects over 24 years of prospective follow-up Tipo de documento: texto impreso Autores: Christina M. Temes, Autor ; Frances R. Frankenburg, Autor ; Garrett M. Fitzmaurice, Autor Fecha de publicación: 2019 Artículo en la página: pp. 30-36 Idioma : Inglés (eng) Palabras clave: Trastorno limite de personalidad - suicidio, Muerte prematura. Resumen: This study has 4 aims. The first is to determine rates of mortality due to suicide and other causes for patients with borderline personality disorder (BPD) and personality-disordered comparison subjects over 24 years of prospective follow-up. Link: ./index.php?lvl=notice_display&id=20475 [artículo] Deaths by suicide and other causes among patients with borderline personality disorder and personality-disordered comparison subjects over 24 years of prospective follow-up [texto impreso] / Christina M. Temes, Autor ; Frances R. Frankenburg, Autor ; Garrett M. Fitzmaurice, Autor . - 2019 . - pp. 30-36. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 30-36 Palabras clave: Trastorno limite de personalidad - suicidio, Muerte prematura. Resumen: This study has 4 aims. The first is to determine rates of mortality due to suicide and other causes for patients with borderline personality disorder (BPD) and personality-disordered comparison subjects over 24 years of prospective follow-up. Link: ./index.php?lvl=notice_display&id=20475

Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia / Christoph U. Correll en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No.1 (Enero - Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 37-44 Título : Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia : Additional Results From the KINECT 3 Study Tipo de documento: texto impreso Autores: Christoph U. Correll, Autor ; Andrew J. Cutler, Autor ; John M. Kane, Autor Fecha de publicación: 2019 Artículo en la página: pp. 37-44 Idioma : Inglés (eng) Palabras clave: Valbenazina, Discinesia tardía - tratamiento Resumen: In the KINECT 3 (NCT02274558; October 2014 to September 2015) study, valbenazine efficacy in tardive dyskinesia (TD) was demonstrated based on mean changes from baseline in the Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1–7). Link: ./index.php?lvl=notice_display&id=20476 [artículo] Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia : Additional Results From the KINECT 3 Study [texto impreso] / Christoph U. Correll, Autor ; Andrew J. Cutler, Autor ; John M. Kane, Autor . - 2019 . - pp. 37-44. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 37-44 Palabras clave: Valbenazina, Discinesia tardía - tratamiento Resumen: In the KINECT 3 (NCT02274558; October 2014 to September 2015) study, valbenazine efficacy in tardive dyskinesia (TD) was demonstrated based on mean changes from baseline in the Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1–7). Link: ./index.php?lvl=notice_display&id=20476

Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia / Fumiaki Kumagai en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No.1 (Enero - Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 45-50 Título : Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia : Combined Analysis of 4 RCTs Tipo de documento: texto impreso Autores: Fumiaki Kumagai, Autor ; Takefumi Suzuki, Autor ; Wolfgang Fleischhacker, Autor Fecha de publicación: 2019 Artículo en la página: pp. 45-50 Idioma : Inglés (eng) Palabras clave: Antipsicotico inyectable + placebo, Esquizofrenia. Resumen: Placebo effects remain largely unexplored in clinical trials of long-acting injectable (LAI) antipsychotics for schizophrenia. This study aims to characterize patients showing improvements after placebo injections and to search for criteria for the prediction of subsequent response based on the magnitude of score changes after the first week of treatment. Link: ./index.php?lvl=notice_display&id=20477 [artículo] Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia : Combined Analysis of 4 RCTs [texto impreso] / Fumiaki Kumagai, Autor ; Takefumi Suzuki, Autor ; Wolfgang Fleischhacker, Autor . - 2019 . - pp. 45-50. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 45-50 Palabras clave: Antipsicotico inyectable + placebo, Esquizofrenia. Resumen: Placebo effects remain largely unexplored in clinical trials of long-acting injectable (LAI) antipsychotics for schizophrenia. This study aims to characterize patients showing improvements after placebo injections and to search for criteria for the prediction of subsequent response based on the magnitude of score changes after the first week of treatment. Link: ./index.php?lvl=notice_display&id=20477